NeuroOne introduces five members of Artificial Intelligence Advisory Board focused on AI and neuromodulation applications
EDEN PRAIRIE, Minn., Nov. 13, 2018 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NMTC), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, introduced five members that have been appointed to the Company’s new Artificial Intelligence Advisory Board.
In the third quarter of 2018, the Company announced the formation of a seven member advisory board to be chaired by Dr. Kip Ludwig of the Bioelectronic Medicines Laboratory at the University of Wisconsin. The advisory board will provide guidance to the Company on the potential use of NeuroOne’s electrode technology in bioelectronics, neuromodulation and artificial intelligence applications. They will also assist the Company with evaluating additional translational science applications for the Company’s electrode technology beyond the initial diagnostic and therapeutic indications.
Five of the members that have been appointed to the advisory board are as follows:
- Dr. Doug Weber, Associate Professor, Department of Bioengineering at the University of Pittsburgh. Recent Program Manager in the Biological Technologies Office (BTO) at the Defense Advanced Research Projects Agency (DARPA).
- Dr. Cristin Welle, Assistant Professor of Neurosurgery at the University of Colorado, Anschutz Medical Campus. Founder of the Neural Interfaces Program at the FDA Center for Devices and Radiological Health Office of Science and Engineering Labs.
- Dr. R. Jacob Vogelstein, Portfolio Manager at Camden Partners Holdings. Recipient of the Presidential Early Career Award in Science and Engineering, 2017.
- Dr. Ayman Salem, Board Certified Neurosurgeon, CEO & Founder of ikioo Technologies, Inc.
- Dr. Joost Wagenaar, co-founder, VP of Scientific Applications at Blackfynn, Inc. Adjunct Assistant Professor of Neurology at the University of Pennsylvania.
NeuroOne CEO Dave Rosa said, “I’m elated that we were able to establish an advisory board with such depth and breadth of expertise. I look forward to working with these experts as we explore expanded opportunities for our thin-film hi-definition electrode technology.”
“These researchers and practitioners are joining us at an exciting time,” said Dr. Ludwig. “Our understanding of the human brain is growing quickly, but many applications have been limited by existing electrode technology and materials. NeuroOne has the opportunity to change that, and I look forward to the potential innovations that will emerge in the coming years.”
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from Epilepsy, Parkinson’s Disease, Essential Tremors and other related neurological disorders that may improve patient outcomes and reduce procedural costs.
Forward Looking Statement
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company’s business strategy, market size, potential growth opportunities, plans for product applications and product development, the use of electrode technology in artificial intelligence and bioelectronics applications, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval, commercialization of the technology, future operations, future efficiencies, and other financial and operating information. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including our ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, our ability to serve those markets, the rate and degree of market acceptance of our products, clinical trial patient enrollment, the results of clinical trials, the actions of third-party clinical research organizations, suppliers and manufacturers, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward‐looking statements speak only as of the date of this press release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.